Healthcare >> Analyst Interviews >> May 13, 2003

Investing In Biotechnology: Srinivas Akkaraju – J.p. Morgan Partners

SRINIVAS AKKARAJU joined the Life Sciences team in the Healthcare Group at J.P. Morgan Partners, LLC, in April 2001. From October 1998 to April 2001, he was in the Business and Corporate Development Group at Genentech, Inc., most recently as Senior Manager. There Dr. Akkaraju was responsible for worldwide partnering activities including technology access deals, in-licensing of early and late-stage therapeutics, and out-licensing of Genentech development projects. In addition to his business development role, he also served for the last year as Project Team Leader for one of Genentech's clinical development products. During this time, Dr. Akkaraju was also a founding member of BioStreet, an online marketplace for biotech opportunities. Prior to joining Genentech in 1998, Dr. Akkaraju was a graduate student at Stanford University, where he earned his MD and PhD in Immunology. Dr. Akkaraju earned his undergraduate degrees in Biochemistry and Computer Science from Rice University in 1990. Profile
TWST: Would you give us a broad idea of what JP Morgan Partners is

doing, particularly as it relates to health and life sciences in

biotechnology?

Dr. Akkaraju: JP Morgan Partners is a